ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese

International Journal of Clinical and Experimental Medicine

Volumn 5, Issue 2, 2012, Pages 186-194

  Chai, Haina ^a,b   Pan, Jie ^c   Zhang, Xuelin ^d   Zhang, Xiaoyan ^b   Shen, Xiaoying ^b   Li, Hang ^b   Zhang, Kehao ^b   Yang, Changqing ^a   Sheng, Haihui ^b   Gao, Hengjun ^a,b  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^b NATIONAL ENGINEERING CENTER FOR BIOCHIP AT SHANGHAI   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

^d TAIZHOU CENTRAL HOSPITAL   (China)

Author keywords

5 FU; Drug response; ERCC1; Molecular biomarker; Platinum; Single nucleotide polymorphism

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHINESE; COLORECTAL CANCER; CONTROLLED STUDY; DNA MICROARRAY; DPYD GENE; DRUG WITHDRAWAL; ERCC1 GENE; FEMALE; GASTROINTESTINAL TOXICITY; GENETIC VARIABILITY; GENOTYPE; GSTP1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; MTHFR GENE; NEUROTOXICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR GENE; TYMS GENE; UGT1A1 GENE; XRCC1 GENE;

EID: 84859955093     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ and Whelton PK. Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124-1134.
2. American Cancer Society. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society. 2007; 12-13.
3. Steward BW and Kleihues P. World Cancer Report. Lyon: IARC Press. 2003; 198-202.
4. Kalow W, Tang BK and Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8: 283-289.
5. Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E and Enerback C. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Clin Biochem 2010; 43: 331-334.
6. Wen SY, Wang XY, Zhang ML and Wang SQ. Frequency Detection of The Known DPYD Alleles in The Studied Subjects Using Oligonucleotide Microarray. Prog Biochem Biophys 2004; 31: 1031 -1036.
7. Zhang H, Li YM and Jin X. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 2007; 24: 251-258.
8. Lee JH, Park JH, Jung Y, Kim JH, Jong HS, Kim TY and Bang YJ. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 2006; 5: 3085-3095.
9. Kristensen MH, Weidinger M, Bzorek M, Peder-sen PL and Mejer J. Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas. J Int Med Res 2010; 38: 484-497.
10. Dotor E, Cuatrecases M, Martinez-Iniesta M, Navarro M, Vilardell F, Guino E, Pareja L, Fi-gueras A, Mollevi DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germa JR, Capella G and Villanueva A. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24: 1603-1611.
11. Cui YH, Liu TS, Zhuang RY, Gao HJ and Li H. Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer. J Dig Dis 2009; 10: 118-123.
12. Hur H, Kang J, Kim NK, Min BS, Lee KY, Shin SJ, Keum KC, Choi J, Kim H, Choi SH and Lee MY. Thymidylate synthase gene polymorphism affects the response to preoperative 5-Fluorouracil chemoradiation therapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2011; 81: 669-676.
13. Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hem-minki K and Kumar R. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol 2011; 18: 2688-2698.
14. Goode EL, Ulrich CM and Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513-1530.
15. Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, Gonzalez S, Guino E, Capella G and Canzian F. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 2006; 12: 2101-2108.
16. Okuda K, Sasaki H, Hikosaka Y, Kawano O, Yu-kiue H, Yano M and Fujii Y. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res 2011; 168: 206-212.
17. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J and Wrensch M. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Bio-markers Prev 2000; 9: 843-847.
18. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F and Reed E. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000; 16: 555-560.
19. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK and Song Y. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and metaanalysis. Med Oncol 2011; 28: 315-321.
20. Saip R, Sen F, Vural B, Ugurel E, Demirkan A, Derin D, Eralp Y, Camlica H, Ustuner Z and Oz-bek U. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients. J BUON 2011; 16: 241-246.
21. Soh TI and Yong WP. Germline genetic testing to predict drug response and toxicity in oncology-reality or fiction? Ann Acad Med Singapore 2011; 40: 350-356.
22. Miller AB, Hoogstraten B, Staquet M and Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
23. Qin S, Zhao X, Pan Y, Liu J, Feng G, Fu J, Bao J, Zhang Z and He L. An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur J Hum Genet 2005; 13: 807-814.
24. Jiang X, Sheng HH, Lin G, Li J, Lu XZ, Cheng YL, Huang J, Xiao HS and Zhan YY. Effect of reninangiotensinaldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. Chin Med J (Engl) 2007; 120: 782-786.
25. Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sanchez-Torres JM, Baron FJ, Cobo M, Maestu I, Moreno I, Mesia C, Izquierdo A, Felip E, Lopez-Brea M, Marquez A, Sanchez-Ronco M, Taron M, Santarpia MC and Rosell R. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011; 71: 191-198.
26. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Bei-jnen JH, Punt CJ, Schellens JH and Cats A. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17: 3455-3468.
27. Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK and Chung HC. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 2009; 20: 272-277.
28. Chang H, Rha SY, Jeung HC, Im CK, Noh SH, Kim JJ and Chung HC. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Rep 2010; 23: 271-278.
29. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A and Praz F. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005; 11: 6212-6217.
30. Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ and Iacopetta B. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 2009; 101: 998-1004.